TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness
Retrieved on:
Thursday, September 22, 2022
University, Biotechnology, Education, Health, Publishing, Radiology, Pharmaceutical, Oncology, Communications, Research, Science, Proton, Neutron, DU145, Health, Alpha, X-ray, Journal, MD Anderson Cancer Center, Proton therapy, Department, Sale, Boron, BNCT, PBCT, BPA, Radiation-induced cancer, Research, Neutron capture therapy of cancer, Radiation, Journal of Medical Physics, Economics, Monroe Dunaway Anderson, University, Neoplasm, Immortalised cell line, Patient, Cancer, TLS, CEO, BSH, Technology, LET, Associate professor, Physics, Doctor of Philosophy, Medical physics, DNA repair, DNA, Prostate cancer, Medical imaging
Proton Boron Capture Therapy (PBCT) is a novel approach of particle therapy aimed at enhancing proton biological effectiveness by exploiting the fusion reaction between low-energy protons and a boron drug to destroy cancer cells via radiation delivery.
Key Points:
- Proton Boron Capture Therapy (PBCT) is a novel approach of particle therapy aimed at enhancing proton biological effectiveness by exploiting the fusion reaction between low-energy protons and a boron drug to destroy cancer cells via radiation delivery.
- TAE Life Sciences and the Department of Radiation Physics at The University of Texas MD Anderson Cancer Center conducted a study, Effect of boron compounds on the biological effectiveness of proton therapy , to identify whether PBCT will produce an increased biological effect in destroying the tumor.
- "TAE Life Sciences is proud of this proton boron fusion study, said Bruce Bauer, PhD, CEO of TAE Life Sciences.
- TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).